Literature DB >> 12883040

Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease.

Ursula R Kees1, Jette Ford, Marcia Watson, Ashleigh Murch, Markus Ringńer, Robert L Walker, Paul Meltzer.   

Abstract

The development of new drugs against cancer requires established cell lines. They are needed for in vitro studies to identify candidate drugs and in xenograft models to measure drug efficacy in vivo. Specific criteria need to be fulfilled by cell lines used in the evaluation of potential novel therapeutic agents. It is imperative that they display the features of the particular cancer under investigation. Given the documented heterogeneity of cancers, relevant subtypes need to be represented. In this study, we have examined these aspects for pediatric acute lymphoblastic leukemia. A panel of 13 leukemia cell lines recently established in our laboratory was analyzed. We used cDNA microarrays to define the gene expression profiles and compared the data with immunophenotyping and cytogenetic analyses. The expression profiles obtained showed excellent concordance with corresponding protein levels. Importantly, the panel of lines displayed the critical genetic features identified in clinically important acute lymphoblastic leukemia subtypes in childhood leukemia patients.

Entities:  

Mesh:

Year:  2003        PMID: 12883040

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  12 in total

1.  Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.

Authors:  Lucine Fahy; Julien Calvo; Sara Chabi; Laurent Renou; Charly Le Maout; Sandrine Poglio; Thierry Leblanc; Arnaud Petit; André Baruchel; Paola Ballerini; Irina Naguibneva; Rima Haddad; Marie-Laure Arcangeli; Frederic Mazurier; Francoise Pflumio; Benjamin Uzan
Journal:  Blood Adv       Date:  2021-01-26

2.  Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.

Authors:  Michelle J Henderson; Klaartje Somers; Mawar Karsa; Angelika Kosciolek; Angelika Bongers; Anna Mariana; Tim Failes; Andrew J Gifford; Ursula R Kees; Laurence C Cheung; Rishi S Kotecha; Greg M Arndt; Michelle Haber; Murray D Norris; Rosemary Sutton; Richard B Lock
Journal:  Br J Cancer       Date:  2021-04-09       Impact factor: 7.640

3.  Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.

Authors:  Klaartje Somers; Kathryn Evans; Richard B Lock; Michelle J Henderson; Leanna Cheung; Mawar Karsa; Tara Pritchard; Angelika Kosciolek; Angelika Bongers; Ali El-Ayoubi; Helen Forgham; Shiloh Middlemiss; Chelsea Mayoh; Luke Jones; Mahima Gupta; Ursula R Kees; Olga Chernova; Lioubov Korotchkina; Andrei V Gudkov; Stephen W Erickson; Beverly Teicher; Malcolm A Smith; Murray D Norris; Michelle Haber
Journal:  Leukemia       Date:  2019-12-17       Impact factor: 12.883

4.  Translating microarray data for diagnostic testing in childhood leukaemia.

Authors:  Katrin Hoffmann; Martin J Firth; Alex H Beesley; Nicholas H de Klerk; Ursula R Kees
Journal:  BMC Cancer       Date:  2006-09-26       Impact factor: 4.430

5.  Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.

Authors:  A H Beesley; M-L Palmer; J Ford; R E Weller; A J Cummings; J R Freitas; M J Firth; K U Perera; N H de Klerk; U R Kees
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

6.  COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Authors:  Kowthar Y Salim; Saman Maleki Vareki; Wayne R Danter; James Koropatnick
Journal:  Oncotarget       Date:  2016-07-05

7.  Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.

Authors:  A H Beesley; M J Firth; J Ford; R E Weller; J R Freitas; K U Perera; U R Kees
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

8.  Finding minimum gene subsets with heuristic breadth-first search algorithm for robust tumor classification.

Authors:  Shu-Lin Wang; Xue-Ling Li; Jianwen Fang
Journal:  BMC Bioinformatics       Date:  2012-07-25       Impact factor: 3.169

9.  Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.

Authors:  M N Cruickshank; J Ford; L C Cheung; J Heng; S Singh; J Wells; T W Failes; G M Arndt; N Smithers; R K Prinjha; D Anderson; K W Carter; A M Gout; T Lassmann; J O'Reilly; C H Cole; R S Kotecha; U R Kees
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

10.  CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.

Authors:  Klaartje Somers; Daria A Chudakova; Shiloh M C Middlemiss; Victoria W Wen; Molly Clifton; Alan Kwek; Bing Liu; Chelsea Mayoh; Angelika Bongers; Mawar Karsa; Sukey Pan; Sarah Cruikshank; Marissa Scandlyn; Wendi Hoang; Toshihiko Imamura; Ursula R Kees; Andrei V Gudkov; Olga B Chernova; Michelle Haber; Murray D Norris; Michelle J Henderson
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.